The Cancer Vaccine That Could Save Moderna
Coming soon to iPhone. Already have it? “Listen in Starcast” takes you straight there.
On this episode
About this episode
For years, Moderna was a one-hit wonder, a company that bet everything on mRNA, struck gold with a COVID vaccine and then watched its stock crater as the pandemic faded. Now, the company may have found a way to fight skin cancer. An experimental mRNA-based vaccine succeeded in preventing melanoma from returning in high-risk patients, sending drug industry stocks soaring. WSJ’s Xavier Martinez traces Moderna’s wild ride from scrappy startup to the frontier of cancer treatment. Ryan Knutson hosts. Further Listening: - The FDA Commissioner on Vaccines and Public Trust - The Creator of the Record-Setting Covid Vaccine Sign up for WSJ’s free What’s News newsletter. Learn more about your ad…